Webinars

Prescription benefits continue to evolve, and the new Trump administration introduces policy changes that could impact costs and regulations. This session will explore the latest developments and what to expect moving forward, with a primary focus on the rising cost of prescription drugs and its effect on group health plans. As patents for many biologic drugs expire, biosimilar alternatives are entering the market at more competitive price points. We will examine strategies within the Prescription Benefit Management (PBM) space, including key considerations for PBM carveouts, program offerings, and the differences between various PBM models to help employers optimize their benefits approach.

Key Learning/Takeaways:

1. Regulatory Impact of the New Administration – Understand how policy changes under the new administration may affect group health plans and prescription benefit regulations.

2. Comparing PBM Models – Learn how to evaluate Transparent (Cost-Based) PBMs versus Traditional PBMs to determine the best fit for your organization.

3. Prescription Cost Containment Strategies – Explore available cost-saving solutions and their potential impact on prescription drug expenses within group plans.

4. The Future of Biologics and Biosimilars – Discover how the expiration of biologic drug patents and the rise of biosimilars may drive changes in pharmaceutical costs and group benefit structures.